Home People Investors Partners AAIP Jobs @ Alloksys Contact News
Investor Relations

For more information regarding investments in Alloksys Life Sciences bv please contact the following persons. You can also fill in the form at the contact page

Office Alloksys Life Sciences BV


ruud@alloksys.com
+31-(0)30-2533615
+31-(0)6-47228395


Paul Hamm


paul@alloksys.com
+32 (0)4 73494397
+31(0)6 42038273


 

 


Press releases

24 nov 2011: Hoopgevend onderzoek aan veelzijdig nieuw type geneesmiddel

Onderzoeksresultaten ondersteunen de theorie dat diverse aandoeningen kunnen worden bestreden of voorkomen door toediening van bepaalde, van nature in het lichaam voorkomende, enzymen. Deze aandoeningen betreffen met name ontstekingsreacties en deze onde...
Read more..


Alloksys Life Sciences announces positive results with alkaline phosphatase in a phase IIa Clinical Trial in Patients undergoing CABG surgery with CPB.

Bunnik, The Netherlands, 23 April 2008 - Dutch biotechnology company Alloksys Life Sciences announces the successful completion of a phase IIa clinical trial (APPIRED) in patients undergoing bypass surgery with cardiopulmonary bypass...
Read more..


Drug development program started based on CAP Human Cell Line. New platform may provide solutions for many RA-patients around the world.

Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the start of Theraptech, a 2.4 million Euro therapeutic protein development program....
Read more..


IBET joins ETB Theraptech project

IBET (Oeiras, Portugal) joins the Theraptech project. Theraptech aims to develop rec human ALP to be applied in arthritides diseases (e.g. RA and ankylosing spondylitis) as a preferred alternative to current TNFa blockers with a different MOA...
Read more..


New Experimental Medicine in EHEC

Bunnik, The Netherlands, June 7, 2011. Dutch biopharmaceutical company Alloksys Life Sciences has an experimental medicine which might help to counteract the effects of an EHEC infection. "We now have over 10 years scientific research .......
Read more..


Nieuw Experimenteel Medicijn in EHEC

Bunnik, 7 juni 2011. Het Nederlandse biotechnologiebedrijf Alloksys Life Sciences heeft een experimenteel medicijn wat mogelijk kan helpen de gevolgen tegen te gaan van een EHEC-besmetting. "We hebben inmiddels meer dan 10 jaar wetenschappelijk .......
Read more..


Alloksys Life Sciences :: Investor Relations